Loading patent…
AssigneeRoche MTM Laboratories AG
InventorsMagnus Von Knebel-Doeberitz, Johannes Gebert, Michael Linnebacher, Stefan Woerner, Ruediger Ridder, Peer Bork, Yan Ping Yuan
Estimating the term…
The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for prevention and curative treatment of cancers and pre-cancers.
A method comprising measuring the presence or absence or level of antibodies or antigen-recognizing cells directed against a frameshift polypeptide in a biological sample from a cancer patient selected from the group consisting of a lung cancer patient, liver cancer patient, renal cancer patient, melanoma patient, cancer of the brain patient, head and neck cancer patient, leukemia patient, lymphoma patient, prostate cancer patient, breast cancer patient, ovary cancer patient, endometrial cancer patient, lung cancer patient, and bladder cancer patient, wherein the frameshift polypeptide is derived from a frameshift mutation in the A11 repeats in a coding microsatellite region of a gene selected from the group consisting of TAF1B, MACS, and HT001.
Dependencies are inferred from the claim text.